MDxHealth (NASDAQ:MDXH) Coverage Initiated at Lake Street Capital

Lake Street Capital initiated coverage on shares of MDxHealth (NASDAQ:MDXH) in a report released on Thursday, MarketBeat reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. Lake Street Capital’s price target would suggest a potential upside of 236.54% from the stock’s current price.

MDxHealth Trading Up 2.5 %

MDXH stock opened at $2.08 on Thursday. The stock has a 50-day moving average price of $2.37 and a two-hundred day moving average price of $2.60. MDxHealth has a 1 year low of $1.95 and a 1 year high of $4.64.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Wednesday, August 21st. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.05). The firm had revenue of $22.16 million for the quarter, compared to the consensus estimate of $20.66 million. MDxHealth had a negative return on equity of 987.86% and a negative net margin of 50.54%. As a group, equities research analysts forecast that MDxHealth will post -1.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MDxHealth stock. MVM Partners LLC lifted its holdings in shares of MDxHealth SA (NASDAQ:MDXH) by 3.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,700,457 shares of the company’s stock after buying an additional 150,000 shares during the period. MDxHealth comprises 10.6% of MVM Partners LLC’s holdings, making the stock its 2nd largest position. MVM Partners LLC’s holdings in MDxHealth were worth $9,706,000 as of its most recent SEC filing.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.